PFA AUDITED RESULTS FOR THE F.Y. ENDED 31.03.2026

MPS Pharmaa (formerly Advik Laboratories) reported a net loss of Rs 102.00 Lacs for FY ended March 2026, worsening from Rs 89.79 Lacs loss in the prior year. Total income stood at just Rs 3.56 Lacs (down from Rs 4.77 Lacs), reflecting virtually zero revenue from business operations. The company's auditors issued a Qualified Opinion citing two issues: (1) investments of Rs 53.80 Lacs in unquoted equity shares that cannot be physically verified or fairly valued under IndAS, and (2) stalled Capital Work in Progress of Rs 2.41 Crore requiring impairment evaluation. The auditors also included an Emphasis of Matter noting the company has had no income from business operations for a long time. Net worth has eroded to just Rs 6.85 Lacs, and the company has not paid BSE listing fees since FY 2021-22, resulting in scrip suspension with only weekly trade-for-trade trading permitted. Related party transactions include unsecured loans to the Managing Director, CFO, and Company Secretary.